

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF CR BOYA BIO-PHARMACEUTICAL FOR THE THREE MONTHS ENDED 31 MARCH 2023

On 10 April 2023, CR Boya Bio-pharmaceutical released its results estimate for the three months ended 31 March 2023.

China Resources Boya Bio-pharmaceutical Group Company Limited (華潤博雅生物製藥集團股份有限公司) (“**CR Boya Bio-pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of CR Boya Bio-pharmaceutical are listed on the Shenzhen Stock Exchange. As of the date of this announcement, China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) indirectly holds approximately 29.28% of the total share capital and approximately 40.59% voting rights in the total share capital of CR Boya Bio-pharmaceutical, and therefore, CR Boya Bio-pharmaceutical is a subsidiary of the Company.

On 10 April 2023, CR Boya Bio-pharmaceutical released its results estimate for the three months ended 31 March 2023, in which, it announced that the net profit attributable to the shareholders of CR Boya Bio-pharmaceutical for the three months ended 31 March 2023 is estimated to range from approximately RMB165.68 million to RMB176.035 million (as compared to the same period last year of net profit of approximately RMB103.55 million), and net profit excluding non-recurring gain or loss is estimated to range from approximately RMB135.4375 million to RMB146.2725 million (as compared to the same period last year of net profit of approximately RMB108.35 million) (the “**CR Boya Bio-pharmaceutical Results Estimate**”).

The main reasons for the change in results are set forth as follows:

1. Blood Products Business

The net profit of the blood products business of CR Boya Bio-pharmaceutical, after deducting and offsetting dividends from subsidiaries of approximately RMB113 million on consolidated level, increased by approximately RMB67.12 million as compared to the same period last year, representing an increase of approximately 72.83%. Such increase is mainly attributable to the greater increase in sales of intravenous immunoglobulin, PCC, and rabies immunoglobulin as compared to the same period last year, and the impact of different structure of financial products on its income derived from financial products.

2. Non-Blood Products Business

The net profit of CR Boya Bio-pharmaceutical’s Fuda Pharmaceutical distribution business increased by approximately RMB4.6522 million as compared to the same period last year, representing an increase of approximately 46.87%, which is mainly due to the increase in sales of intravenous immunoglobulin and albumin products. The revenue and net profit of other non-blood products businesses remained stable.

CR Boya Bio-pharmaceutical estimates its non-recurring losses to be approximately RMB32.2 million for the first quarter of 2023.

CR Boya Bio-pharmaceutical Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. The quarterly report for the three months ended 31 March 2023 to be disclosed by CR Boya Bio-pharmaceutical shall prevail.

The financial information in this announcement is limited to CR Boya Bio-pharmaceutical only and does not represent or provide a complete view of the operational of financial status of the Group. **Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

For further details of the CR Boya Bio-pharmaceutical quarterly financial information, please refer to the quarterly report for the three months ended 31 March 2023 to be published by CR Boya Biopharmaceutical on the website of the Shenzhen Stock Exchange (www.szse.cn).

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 10 April 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.